Page 60 - Read Online
P. 60

Scotti et al. Vessel Plus 2021;5:6  I  http://dx.doi.org/10.20517/2574-1209.2020.68                                                  Page 7 of 10













                     Exclusion Criteria Stroke/TIA (3 months) or Modified Rankin Scale ≥ 4 disability; AMI  (30 days); heart valve surgery or TC MV intervention; percutaneous CV  intervention, CV surgery, or carotid surgery (30 days); rheumatic heart  disease or endocarditis (3 months); hypertrophic/restrictive cardiomyopathy,  constrictive pericarditis, or any HF cause other than dilated cardiomyopathy;  inferior vena cava filter or atrial septal device; clinically signi











                                                             mL/min/1.73 m 2           unsuitable anatomy  days)  active endocarditis; creatinine > 2.5 mg/dL






                         Age ≥ 18 years; NYHA II, III or amb. IV; MR  3-4 +; GDMT and/or CRT; high surgical  risk; TEE feasible; anatomical eligibility;  suitable for femoral access procedure and   TS catheterization  ≥ 18 years; severe MR; Cardiac Index > 2.0;  EF ≥ 30%; NYHA II, III or amb. IV; GDMT  (30 days); high surgical risk  IV; GDMT; surgical high-risk; anatomical  eligibility; DMR: EROA ≥ 40 mm 2  or  regurgitant Vol. ≥ 60 mL; SMR: EROA > 30  mm 2  or regurgitan



                 Table 1. Ongoing active clinical trials investigating transcatheter mitral valve replacement devices*
                     Inclusion Criteria     NCT03813524 and NCT03958773: 85 > age   Age ≥ 18 years; MR ≥ 3 +; NYHA II, III, amb.   Age ≥ 18 years; severe MR; high surgical risk;   risk; anatomical eligibility; NYHA III or IV HF Age ≥ 18 years; severe MR; NYHA II, III, IVa











                     Primary Outcome (Primary   Completion)  Mortality, MACE,  hospitalization, and device or  procedural serious adverse  events (15 December 2020)  Technical success and major  device related adverse events   (30 days) (April 2022)  Major device related adverse   events (30 days) (12   September 2020)  MACE at 30 days (July 2021)  MACE and device safety at   30 days (April 2021)  Major adverse events at 30   days (July 2021)  MACE, all-cause mortality,













                     Status (patients)  Recruiting (30) NCT03339115  Recruiting (15) NCT03813524  Recruiting (10) NCT03958773  Recruiting (50) NCT02974881  Not yet recruiting (15)   NCT04029337   Recruiting (50) NCT04029363  Active, not recruiting (115)   NCT03039855  Active, not recruiting (30)   NCT02276547  Active, not recruiting (20)   NCT02768402   Active, not recruiting (75)   NCT03661398  Active, not recruiting (10)   NCT02428010











                     Device   (Access)  Cardiovalve  (TS)      HighLife  (TS)  Tiara  (TA)  Caisson  (TS)  Twelve  (TA)
   55   56   57   58   59   60   61   62   63   64   65